Compare SLND & JSPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SLND | JSPR |
|---|---|---|
| Founded | 1900 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 31.4M | 26.3M |
| IPO Year | 2021 | 2019 |
| Metric | SLND | JSPR |
|---|---|---|
| Price | $0.67 | $0.70 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 11 |
| Target Price | $4.00 | ★ $15.50 |
| AVG Volume (30 Days) | 574.3K | ★ 681.3K |
| Earning Date | 05-11-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 19.22 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $772,168,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $9.59 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.51 | $0.32 |
| 52 Week High | $5.34 | $3.05 |
| Indicator | SLND | JSPR |
|---|---|---|
| Relative Strength Index (RSI) | 49.82 | 48.88 |
| Support Level | $0.64 | $0.59 |
| Resistance Level | $0.75 | $1.03 |
| Average True Range (ATR) | 0.08 | 0.12 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 63.84 | 30.14 |
Southland Holdings Inc is an infrastructure construction company in North America. The company's infrastructure projects range from water conveyance systems and tunnels to long-span bridges and vertical structures. The company operates in two distinct segments: Civil and Transportation. The civil segment operates throughout North America and specializes in services that include the design and construction of water pipelines, pump stations, lift stations, water and wastewater treatment plants, concrete and structural steel, outfall, and tunneling. The transportation segment operates throughout North America and specializes in services that include the design and construction of bridges, roadways, marine, dredging, ship terminals and piers, and specialty structures and facilities.
Jasper Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics targeting mast cell driven diseases such as Chronic Spontaneous Urticaria (CSU), Chronic Inducible Urticaria (CIndU) and asthma. The company's lead product candidate, briquilimab, is a monoclonal antibody designed to block stem cell factor (SCF) from binding to and signaling through the CD117 (KIT) receptor on mast and stem cells. The company has a single operating and reportable segment, which is the research and development of therapeutic products in the fields of chronic urticaria and asthma.